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1. Introduction 
The existence of a specific carrier for pyruvate in 
the inner membrane of rat liver mitochondria is now 
well established [l-4] . Based on indirect evidence it 
has been suggested that glucagon, adrenaline or 
dibutyryl cyclic AMP act on liver cells to stimulate 
the operation of the mitochondrial pyruvate carrier 
and that this effect is involved in the increase in the 
rate of gluconeogenesis which follows exposure to 
those agents [.5,6]. In an earlier paper [7] we obtained 
direct evidence for this suggestion. Glucagon was 
injected into rats and 30 min later the livers were 
removed and mitochondria were prepared. We observed 
increased maximum initial rates of pyruvate transport 
into these mitochondria compared to mitochondria 
from control rat livers. The increased mobility of the 
pyruvate carrier was not due to preaccumulation of 
counter ions - pyruvate, malate or palmitoyl carnitine 
within the mitochondrial matrix - but an increased 
hydroxyl anion concentration therein was not excluded. 
We now report experiments of similar design in which 
injection of adrenaline or production of diabetes by 
streptozotocin injection also led to increases in initial 
rates of mitochondrial pyruvate transport. We have 
also measured various other parameters of mitochondrial 
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behaviour which may be relevant to changes in 
mobility of the pyruvate carrier. 
2. Methods and materials 
Methods and materials were as in our earlier papers 
[4,7] with the following additions. Published methods 
were used to determine mitochondrial matrix space 
[8], membrane potential [9] and pH gradient [9]. 
Pyruvate dehydrogenase was measured in extracts of 
freeze-clamped liver and mitochondria by the method 
of Coore et al., [lo] . Extraction and assay of ‘initial’ 
and ‘total’ pyruvate dehydrogenase in freeze-clamped 
tissue were earlier described [ 111. ‘Initial’ activity of 
mitochondrial pyruvate dehydrogenase was measured 
in mitochondria following 5 min incubation in the 
medium used for measurements of pyruvate decarboxy- 
lation by rapid (20 s) centrifugation, freezing of the 
pellet in liquid nitrogen and freeze-thawing three times 
in 500 1.11 of 50 mM Tris-HCl, 5 mM EDTA, 1 mM 
dithiothreitol, pH 7.0 and 2 ~1 of rat serum. ‘Total’ 
activity of pyruvate dehydrogenase in the mitochondria 
was assumed to be achieved when 50 yM 2-4-dinitro- 
phenol was included in the incubation medium cf. [ 121 
and the mitochondria were extracted as detailed above. 
Adrenaline was obtained from British Drug Houses, 
Poole, Dorset, UK; glucagon was from Eli Lilly, 
Basingstoke, UK and propranolol from I.C.I. 
Macclesfield, Cheshire, UK. Streptozotocin was kindly 
donated by Upjohn Ltd., Kalamazoo, Mich., USA and 
soluble insulin was from Burroughs Wellcome & Co., 
London, N.W.I., UK. All radiochemicals were from 
Amersham Radiochemicals, Amersham, UK. 
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3. Results and discussion 
3.1. Effects of adrenaline injection on rates of pyruvate 
uptake and decarboxylation by isolated mito- 
chondria 
Table 1 shows that 30 mm exposure of liver in vivo 
to a high dose of adrenaline was sufficient to induce 
persistent significant effects on both parameters. 
Unlike the earlier experience with glucagon injections 
[7] we find a discrepancy in magnitude of stimulation 
of decarboxylation (67%) with that of initial rates of 
uptake (23%) when both are expressed on a protein 
basis. 
The effect of adrenaline injection on pyruvate 
decarboxylation by isolated mitochondria was not 
due to an altered degree of phosphorylation of mito- 
chondrial pyruvate dehydrogenase. We measured the 
‘initial’ activity (expressive of the partially dephospho- 
rylated enzyme) and the ‘total’ pyruvate dehydrogenase 
activity (expressive of the fully dephosphorylated 
enzyme) in mitochondria incubated in conditions 
similar to those used in the experiment 1 of table 1. 
In mitochondria from both control and adrenaline 
treated animals ‘total’ pyruvate dehydrogenase activity 
was about 12 mU/mg protein and the ratio of ‘initial’ 
to ‘total’ enzyme activity was about 70% cf. [ 12,131. 
3.2. Comparison of various parameters of mito- 
chondrial behaviour in mitochondria isolated 
fro& adrenaline or glucagon treated rats 
Table 2 shows that both treatments result in increas- 
ed Oa uptakes by isolated mitochondria incubated in 
state 3 conditions when pyruvate + malate was the 
substrate but not when ascorbate + TMPD was the 
substrate. Yamazaki [ 141 has reported this pheno- 
menon in respect of glucagon treatment. It is evident 
that in both instances the mitochondria were well 
coupled and there was probably no effect of hormonal 
pretreatment on the capacity of the mitochondrial 
electron-transport chain to transmit electrons, at least 
beyond the point of interaction with ascorbate t
TMPD. Yamazaki concluded that the effect of glucagon 
treatment was to promote the entry of carrier-trans- 
ported metabolites into the mitochondria (ascorbate + 
TMPD reacted with cytochrome c on the outer face of 
the inner mitochondrial membrane). Clearly, our 
results for pyruvate uptake are consistent with that 
suggestion. 
Table 1 
Rates of pyruvate uptake and decarboxylation by mitochondria isolated from control or adrenaline treated rats 
Experiment Treatment of rat Rate of “CO, production from Initial rate of Plasma glucose at 
[ l-‘4C]pyruvate by mitochondria [2-“C]pyruvate uptake time when liver 
(nmol/min/mg protein) (nmol/min/mg protein) removed (mM) 
1 Control: 0.01 M HCl 
injection 3.92 * 0.45 (9) _ 8.59 f 0.30 (9) 
Adrenaline (2.5 mg/kg s.c.) 
in 0.01 M HCl injected 6.57 + 0.75 (9)a - 19.74 f 0.10 (9)b 
[67.5 f 9.8%] 
2 Control: 0.01 M HCl 
injection _ 26.8 + 0.3 (10) 8.20 + 0.21 (10) 
Adrenaline (2.5 mg/kg s.c.) 
in 0.01 M HCI injected - 33.0 f 1.8 (lO)a 21.74 + 0.76 (lO)b 
[23.1 f 3.1%] 
Blood was sampled and livers removed 30 min after injections. Details of methods were described earlier [4,7]. Mitochondria 
were incubated in media containing 1.4 mM pyruvate for both experiments but in experiment 1 the incubation temperature was 
30°C whereas it was 27°C for experiment 2. Data (unbracketed) are means + S.E. Numbers of mitochondrial preparations or 
rats are given in round brackets. Percentage ffects compared to controls, calculated on a paired basis for each experimental day, 
are given within square brackets. 
ap < 0.01; 
bp < 0.001 comparing means of data from treated and controls rats. 
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Table 3 
November 19 76 
Matrix volumes, membrane potentials and pH gradients of mitochondria isolated from control or hormone injected rats 
Experiment Treatment of rat Matrix volume 
(PI/ mg protein) 
pH gradient 
(outside-inside) 
Membrane potential 
(mV) 
1 Control; injection of solvent 0.49 + 0.04 (18) -1.22 f 0.04 (8) 139.6 * 1.7 (10) 
Glucagon (300 pg/kg i.p.) 0.52 + 0.09 (8) - 1.42 + 0.06 (7)a 140.8 2 3.2 (4) 
2 Control; injection of solvent 0.49 c 0.04 (18) -1.23 ? 0.04 (8) 139.6 + 1.7 (10) 
Adrenaline (2.5 pg/kg s.c.) 0.31 + 0.03 (8)” -1.29 f 0.04 (8) 144.3 * 2.9 (6) 
Livers were removed for mitochondrial preparation 30 min after injections. Mitochondria were incubated for 2 min with 3 mM 
ascorbate + 0.05 TMPD at 30°C along with appropriate radioactive substances prior to separation from medium by centrifugation 
(20 s). The numbers of mitochondrial preparations are given in parentheses. 
a~ < 0.01 comparing means of data from treated and control rats. 
Since all the carrier-transported metabolites (includ- 
ing pyruvate) studied by Yamazaki may be regarded 
as exchanging directly or indirectly with intra-mito- 
chondrial hydroxyl-anions [ 151 we have measured 
the mitochondrial trans-membrane pH gradient and 
associated parameters. Table 3 shows that under con- 
ditions of stable energy supply (ascorbate + TMPD in 
the incubation medium) mitochondria from livers of 
glucagon treated rats showed a significantly elevated 
pH gradient (compared to mitochondria from control 
animals) which itself would be expected to encourage 
entry of anionic substrates. We can only speculate as 
to the reason for the elevated pH gradient but one 
possibility is that glucagon pretreatment has resulted 
in a decreased back-leakage of extruded protons or a 
decreased proton/K’ exchange. In the case of adrenaline 
treatment a different mechanism is involved. There is 
now no increase of pH gradient but a decrease of 
matrix volume. We may note that if the rate of 
pyruvate uptake is expressed in terms of matrix 
volume instead of mitochondrial protein, mitochondria 
from adrenaline treated rats show a 95% stimulation 
of the rate of pyruvate uptake. The mechanism of this 
adrenaline effect on matrix volume is enigmatic. 
Dolgov [ 161 reported that adrenaline infusion of dog 
hearts resulted in decreased K’ content of the isolated 
mitochondria. Matrix volume was not measured in 
those experiments. If, as in our experiments, mem- 
brane potential and therefore K’ ion distribution was 
unaffected, the lower K’ content noted by Dolgov 
may have simply been a result of a smaller matrix 
volume with a normal K’ concentration. It is con- 
ceivable that following adrenaline treatment in vivo 
76 
there was a transient fall in the mitochondrial mem- 
brane potential with consequent extrusion of K’ and 
shrinkage of the mitochondria to re-establish a new 
equilibrium between proton extrusion and back flow, 
membrane potential, K’ gradients and matrix volume. 
In any case it is not obvious why anion transport 
should be facilitated by such changes. 
3.3. Effects on mitchondrial behaviour of streptozotocin 
diabetes in donor rats 
Table 4 shows that induction of diabetes in the rats 
from which livers were obtained resulted in a time- 
dependent increase in the initial rate of pyruvate 
uptake by isolated mitochondria. Reminiscent of the 
case of adrenaline treatment, there was a small fall 
in the matrix volume of the mitochondria which did 
not attain the 5% level of significance. However, when 
the rates of pyruvate uptake of each preparation were 
expressed per ~1 matrix space for that preparation 
instead of per mg protein, the magnitude of stimulation 
due to 48 h streptozotocin diabetes in donor rats 
increased from below 50% to nearly 100%. 
Because of these latter results we investigated the 
effects on initial rates of pyruvate uptake by mito- 
chondria of injection of soluble insulin (10 I.U.) into 
donor animals 30 and 60 min before sacrifice. 
Although this treatment was adequate to triple the 
proportion of ‘initial’ to ‘total’ pyruvate dehydro- 
genase in freeze-clamped liver cf. [ 171 there was no 
effect on initial rates of mitochondrial pyruvate 
uptake with or without preaccumulation of a counter- 
ion, malate, within the matrix. 
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Table 4 
Initial rates of pyruvate transport in mitochondria isolated from streptozotocin-treated diabetic rats 
Treatment of rat before 
removal of liver 
Initial rate of [2-Y] pyruvate uptake expressed as Mitochondrial Plasma glucose 
matrix space (mM) 
nmol/min/mg protein nmol/min/rl of Wmg) 
matrix space 
Control: Buffer 
injected 3 h, 24 h or 48 h 
before 32.8 * 1.3 (11) 69.7 f 6.3 (10) 0.51 2 0.05 (10) 8.11 ?: 0.23 (11) 
Streptozotocin 
injected 3 h before 38.1 + 6.2 (3) _ _ 17.31 r 5.90 (3) 
Streptozotocin 
injected 24 h before 39.4 f 1.5 (6)b 102.7 f 8.9 (5)b 0.37 * 0.04 (5) 21.03 ? 1.94 (6)’ 
Streptozotocin 
injected 48 h before 46.3 + 2.1 (6)’ 137.6 f 25.3 (6)a 0.40 f 0.07 (6) 24.33 -r 1.08 (6)’ 
Streptozotocin (65 mg/kg i.p.) in 10 mM acetate buffer, pH 4.5 or acetate buffer alone was injected into rats and after the stated 
times the livers were removed and mitochnndria prepared. Details of methods were given earlier [4] and in the Methods and 
materials section of this paper. Data are means f SE with numbers of different mitochondrial preparations orrats given in 
brackets. 
ap < 0.05; 
bp < 0.01; 
‘p < 0.001 comparing means of data from treated and control rats. 
3.4. Relevance of hormonal effects on mitochondrial 
pyruvate transport to regulation of gluconeo- 
genesis and lipogenesis 
It is generally accepted that acute hormonal effects 
on gluconeogenesis involve a metabolic step lying 
between pyruvate and phospho-enol pyruvate [ 181. 
No sufficiently rapid effects on the relevant enzymes 
have been detected except perhaps for pyruvate 
kinase [ 191 and this has led to the view that pyruvate 
transport into the mitochondria is the site of hormonal 
action on the gluconeogenic process [5,6] . Results of 
this and our previous paper [7] give direct support 
for this hypothesis. It is also probable that malate 
exchanges with pyruvate on the pyruvate carrier [7] 
and this would be a neat mechanism to ensure efflux 
of adequate oxaloacetate and reducing power required 
for the further stages of gluconeogenesis. 
The way in which glucagon and adrenaline treat- 
ments alter the mobility of the pyruvate carrier in the 
inner mitochondrial membrane requires further inves- 
tigation. Our results indicate separate mechanisms and 
this is consistent with other work suggesting that the 
effects of the two hormones on gluconeogensis are 
additive [20]. Cyclic AMP may well mediate the 
glucagon effect [6] but probably not that of adrenaline 
since propranolol(l0 mg/kg i.p.) injected 15 min 
before adrenaline did not disturb the effect of the 
hormone on the rate of pyruvate decarboxylation by 
subsequently isolated mitochondria. This dose of 
propranolol is reported [21] adequate for complete 
blockage of the 0 receptor. However, experiments 
involving whole animals are subject to difficulties of 
interpretation due to secondary and tertiary effects 
of any treatment. As noted earlier, in vitro experi- 
ments are required to clarify the mechanism of the 
hormonal effects. This reservation applies also to 
experiments with diabetic rats. It may be that in 
such rats insulin deficiency is not the factor directly 
relevant to control of the mitochondrial pyruvate 
carrier but rather the associated increase in plasma 
glucagon concentration [22]. 
It has been argued [ 171 that pyruvate dehydro- 
genase of liver is rate limiting for synthesis of fatty 
acids from pyruvate. By diminishing the phosphoryla- 
tion of pyruvate dehydrogenase, insulin would be 
expected to promote synthesis of fatty acids from 
pyruvate in liver as well-as in adipose tissue. Our 
results :uggest that the mechanism of insulin action 
on liver pyruvate dehydrogenase does not involve 
persistent alteration of the mobility of the mito- 
chondrial pyruvate carrier. 
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